Welcome to LookChem.com Sign In|Join Free
  • or
2-(N-tert-butylamino)-3'-bromopropiophenone is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1049974-35-7

Post Buying Request

1049974-35-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1049974-35-7 Usage

Molecular Structure

A chemical compound with a tert-butylamino group and a bromine substituent attached to a propiophenone derivative.

Usage

Commonly used in research and pharmaceutical applications as a versatile building block for the synthesis of various bioactive compounds.

Potential

Has potential as a reagent in organic chemistry and as a precursor in the creation of new drugs and pharmaceuticals.

Safety Precautions

Handle with caution and follow safety protocols due to potential health hazards and environmental impact.

Check Digit Verification of cas no

The CAS Registry Mumber 1049974-35-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,9,9,7 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1049974-35:
(9*1)+(8*0)+(7*4)+(6*9)+(5*9)+(4*7)+(3*4)+(2*3)+(1*5)=187
187 % 10 = 7
So 1049974-35-7 is a valid CAS Registry Number.

1049974-35-7Relevant academic research and scientific papers

MONOAM1NE REUPTAKE INHIBITORS

-

Page/Page column 65, (2010/11/04)

The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine,and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity

Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction

Carroll, F. Ivy,Blough, Bruce E.,Abraham, Philip,Mills, Andrew C.,Holleman, J. Ashley,Wolckenhauer, Scott A.,Decker, Ann M.,Landavazo, Antonio,McElroy, K. Timothy,Navarro, Hernán A.,Gatch, Michael B.,Forster, Michael J.

supporting information; experimental part, p. 6768 - 6781 (2010/04/06)

A series of bupropion (1a) analogues (1b-1ff) were synthesized, and their in vitro and in vivo pharmacological properties evaluated with the goal of developing a 1a analogue that had better properties for treating addictions. Their in vitro pharmacological properties were examined by [3H] dopamine ([3H]DA), [3H]serotonin ([3H]5HT), and [3H]norepinephrine ([3H]NE) uptake inhibition studies, and by binding studies at the dopamine, serotonin, and norepinephrine transporters using [125I]RTI-55 in cloned transporters. Several analogues showed increased [3H]DAuptake inhibition with reduced or little change in [3H]5HT and [3H]NE uptake inhibition relative to bupropion. Thirty-five analogues were evaluated in a 1 h locomotor activity observation test and 32 in an 8 h locomotor activity observation test and compared to the locomotor activity of cocaine. Twenty-four analogues were evaluated for generalization to cocaine drug discrimination after i.p. administration, and twelve analogues were tested in a time course cocaine discrimination study using oral administration. 2-(N-Cyclopropylamino)-3- chloropropiophenone (1x) had the most favorable in vitro efficacy and in vivo pharmacological profile for an indirect dopamine agonist pharmacotherapy for treating cocaine, methamphetamine, nicotine, and other drugs of abuse addiction. 2009 American Chemical Society.

Synthesis and evaluation of the anticonvulsant activity of a series of 2-amino-1-phenyl-1-propranols derived from the metabolites of the antidepressant bupropion

Musso, David L.,Mehta, Nariman B.,Soroko, Francis E.

, p. 1 - 6 (2007/10/03)

A series of 2-amino-1-phenyl-1-propanols that are structurally related to known metabolites of bupropion, 1 (Wellbutrin) were synthesized and evaluated as potential anticonvulsants. The (R*,R*)-2-tert-butylamino-1-(3-trifluoromethylphenyl) propanol 20 had an ED50 of 16.5 ± 2.8 mg/kg ip in mice in the maximal electroshock screen and was chosen for further evaluation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1049974-35-7